Efficacy and safety of repaglinide added to sitagliptin in Japanese patients with type 2 diabetes: A randomized 24-week open-label clinical trial

Nishimura, Akihiro; Usui, Shuki; Kumashiro, Naoki; Uchino, Hiroshi; Yamato, Azusa; Yasuda, Daijiro; Nagasawa, Kaoru; Okubo, Minoru; Mori, Yusaku; Hirose, Takahisa

doi:10.1507/endocrj.ej16-0291

Cited by 4 publications

(4 citation statements)

References 39 publications

(50 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The mean ages of the patients varied between 51 and 74 years. Various DPP4 inhibitors were used among these studies, such as vildagliptin, saxagliptin, linagliptin, sitagliptin, alogliptin, teneligliptin, and gemigliptin, whilst placebo was used as the control in all of the included RCTs except one study which received no treatment ( 42 ). The treatment durations varied between 5 and 350 days, and circulating postprandial glucagon was measured with radioimmunoassay in MTT/OGTT settings.…”

Section: Resultsmentioning

confidence: 99%

“…An overview of the included studies can be found in Table 1. Overall, 23 studies compared DPP4 inhibitors with placebo (20-22, 25-27, [30][31][32][33][34][35][36][37][38][39][40][41][42][44][45][46][47]. Eight studies compared DPP4 inhibitors with other OADs (28,(48)(49)(50)(51)(52)(53)(54)(55), and the other five studies included both comparisons with placebo and other OADs (23,24,28,29,43).…”

Section: Study Characteristics and Data Qualitymentioning

confidence: 99%

See 1 more Smart Citation

Effect of dipeptidyl peptidase-4 inhibitors on postprandial glucagon level in patients with type 2 diabetes mellitus: A systemic review and meta-analysis

Chai¹,

Zhang²,

Zhang³

et al. 2022

Front. Endocrinol.

View full text Add to dashboard Cite

AimsHyperglucagonemia occurs in the pathogenesis of type 2 diabetes mellitus (T2DM). In this meta-analysis, we summarized the effects of DPP4 inhibitors on glucagon levels in patients with T2DM.Materials and methodsRandomized controlled trials (RCTs) comparing the influence of DPP4 inhibitors on circulating glucagon levels with placebo or other oral antidiabetic drugs (OADs) in patients with T2DM were identified by searches of Medline (PubMed), Embase (Ovid), and CENTER (Cochrane Library). Only studies reporting changes in glucagon level presented as total area under the curve (AUCglucagon) using a meal or oral glucose tolerance test were included. Results were combined using a random-effects model that incorporated potential heterogeneity among the included studies.ResultsA total of 36 RCTs with moderate to high quality were included. Overall, the numbers of T2DM patients included for the meta-analyses comparing DPP4 inhibitors with placebo and other OADs were 4266 and 1652, respectively. Compared to placebo, DPP4 inhibitors significantly reduced circulating glucagon levels (standard mean difference [SMD]: -0.32, 95% CI: -0.40 to -0.24, P<0.001; I2 = 28%). Analysis of subgroups revealed that study characteristics had no significant effect on results, such as study design (parallel group or crossover), number of patients, mean patient age, proportion of men, baseline HbA1c, duration of diabetes, background therapy, treatment duration, or methods for glucagon measurement (all P for subgroup differences >0.05). Moreover, DPP4 inhibitors significantly reduced glucagon levels compared to other OADs (SMD: -0.35, 95% CI: -0.53 to -0.16, P<0.001; I2 = 66%), and the reduction in glucagon was greater in comparison with insulin secretagogues than in comparison with non-insulin secretagogues (P for subgroup difference =0.03).Systematic review registrationhttps://inplasy.com/, identifier INPLASY202280104.ConclusionsDPP4 inhibitors are effective at reducing the circulating postprandial glucagon level in T2DM patients.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Study Characteristics and Data Qualitymentioning

confidence: 99%

Effect of dipeptidyl peptidase-4 inhibitors on postprandial glucagon level in patients with type 2 diabetes mellitus: A systemic review and meta-analysis

Chai¹,

Zhang²,

Zhang³

et al. 2022

Front. Endocrinol.

View full text Add to dashboard Cite

show abstract

“…When we examined the effects of adding DPP-4 inhibitors in the first year, we also found significant differences between starting and ending HbA1c. Patients had a median improvement of 0.89% over 5 months (2)(3)(4)(5)(6)(7)(8)(9)(10)(11)(12) or 20 weeks. Patients in the vildagliptin subgroup and patients in the sitagliptin subgroup were not statistically different in terms of HbA1c reduction or lipid parameters compared to each other.…”

Section: Discussionmentioning

confidence: 99%

“…Nishimura and colleagues found that the combination of sitagliptin with repaglinide was effective at 24 weeks. 5 Ji L et al, demonstrated the efficacy of coadministration of metformin sitagliptin in multicentre studies at 24 weeks. 6 In another study, insulin glargine and metformin combination were compared with sitagliptin metformin combination in obese DM patients with HbA1c >9.5%.…”

mentioning

confidence: 99%

Are dipeptidyl peptidase-4 inhibitors effective and safe in long term when added to ongoing therapies of diabetics? a real-life study in tertiary referral center

Avcı

Çetinkaya

2019

Int J Adv Med

View full text Add to dashboard Cite

Background: The aim of this study was to determine how HbA1c, lipid, renal functions and such parameters were affected in the long term by adding dipeptidyl peptidase-4 inhibitors to the ongoing treatment regimens of patients with Type 2 diabetes mellitus.Methods: The study was conducted in diabetes mellitus outpatient clinic of Kayseri Training and Research Hospital between February 2012 and May 2017, with patients who did not achieve the sufficient success in diabetes their controls at the time of admission. From these patients, those who added (dipeptidyl peptidase-4 inhibitors) to their treatments were selected. Patients were followed up as long as they continued to these new treatments and the parameters at the baseline were compared with final values.Results: A total of 80 diabetic patients were followed in the study. The median age of the patients was 56.08±9.71 years. During this follow-up, an average decrease of 1.03% was noted when patients were compared with 9.53±1.87% of the initial hemoglobin A1c, and 8.50±1.48% of the Hemoglobin A1c values at the end of follow-up. This decrease was statistically significant (p <0.001). However, differences in the initial and final values of the lipid parameters of the patients were not statistically significant.Conclusions: Addition of dipeptidyl peptidase-4 inhibitors to patients' treatments causes significant decreases in Hemoglobin A1c mean values. This decline is long lasting. However, there are no positive or negative effects on biochemical parameters such as lipids, kidney and liver functions.

show abstract

Characteristics of repaglinide effects on insulin secretion

Takahashi

Hidaka

Seki

et al. 2018

European Journal of Pharmacology

View full text Add to dashboard Cite

Efficacy and safety of repaglinide added to sitagliptin in Japanese patients with type 2 diabetes: A randomized 24-week open-label clinical trial

Cited by 4 publications

References 39 publications

Effect of dipeptidyl peptidase-4 inhibitors on postprandial glucagon level in patients with type 2 diabetes mellitus: A systemic review and meta-analysis

Effect of dipeptidyl peptidase-4 inhibitors on postprandial glucagon level in patients with type 2 diabetes mellitus: A systemic review and meta-analysis

Are dipeptidyl peptidase-4 inhibitors effective and safe in long term when added to ongoing therapies of diabetics? a real-life study in tertiary referral center

Characteristics of repaglinide effects on insulin secretion

Contact Info

Product

Resources

About